Research and Development Institute - IPD, Vale do Paraíba University - UNIVAP, Av. Shishima Hifumi, CEP: 12244-000. São José dos Campos, SP 2911, Brazil.
Research and Development Institute - IPD, Vale do Paraíba University - UNIVAP, Av. Shishima Hifumi, CEP: 12244-000. São José dos Campos, SP 2911, Brazil.
Photodiagnosis Photodyn Ther. 2023 Dec;44:103830. doi: 10.1016/j.pdpdt.2023.103830. Epub 2023 Oct 16.
Hydroxyapatite (HAp) presents similarities with the human bone structure and presents properties such as biodegradability, biocompatibility, and osteoconductivity, which favors its use in prostheses implants and enables its use as a vehicle for the delivery of photosensitizers (PS) from systems of release (DDS) for photodynamic therapy applications Methods: In this work was to synthesized hydroxyapatite microspheres (meHAp), encapsulated with chloroaluminium phthalocyanine (ClAlPc), for DDS. meHAp was synthesized using vaterite as a template. The drug was encapsulated by mixing meHAp and a 50.0 mg.mL ClAlPc solution. Photochemical, photophysical, and photobiological studies characterized the system.
The images from the SEM analysis showed the spherical form of the particles. All spectroscopic results showed excellent photophysical parameters of the drug studied when served in the meHAp system. The incorporation efficiency was 57.8 %. The trypan blue exclusion test results showed a significant reduction (p < 0.05) in cell viability for the groups treated with PDT at all concentrations above 250 μg.mL. In 9 L/lacZ gliosarcoma cells, PDT mediated at concentrations from 250 to 62.5 µg.mL reduced cell viability by more than 98 %. In the cell internalization study, it was possible to observe the internalization of phthalocyanines at 37 °C, with the accumulation of PS in the cytoplasm and inside the nucleus in the two tested concentrations.
From all the results presented throughout the article, the meHAp system shows promise for use as a modified release system (DSD) in photodynamic therapy.
羟基磷灰石（HAp）与人骨结构具有相似性，具有生物降解性、生物相容性和骨传导性等特性，有利于将其用于假体植入，并使其能够作为光敏剂（PS）从释放系统（DDS）递送到用于光动力疗法应用的载体。
在这项工作中，合成了羟基磷灰石微球（meHAp），并用氯铝酞菁（ClAlPc）包封，用于 DDS。meHAp 是使用方解石作为模板合成的。通过混合 meHAp 和 50.0mg.mL ClAlPc 溶液来包封药物。对光化学、光物理和光生物学研究对该系统进行了表征。
SEM 分析的图像显示了颗粒的球形形态。所有光谱结果均显示，当药物在 meHAp 系统中使用时，研究药物具有出色的光物理参数。包封效率为 57.8%。台盼蓝排除试验结果表明，所有浓度高于 250μg.mL 的 PDT 处理组的细胞活力均显著降低（p<0.05）。在 9L/lacZ 神经胶质肉瘤细胞中，浓度为 250 至 62.5μg.mL 的 PDT 可使细胞活力降低 98%以上。在细胞内化研究中，能够观察到在 37°C 时酞菁的内化，两种测试浓度下 PS 都积聚在细胞质和细胞核内。
从整篇文章中呈现的所有结果来看，meHAp 系统有望作为光动力疗法的改良释放系统（DDS）使用。
